Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?

To: Easy Mark who wrote (359)	4/6/1998 5:57:00 PM
From: Easy Mark	Respond to of 1510

GILD was up big on news that Preveon, its anti-viral drug, is effective in combination with other drugs. Preveon competes against the current antivirals and not against Remune. Quote from GILD: "Gilead's PREVEON(TM) (adefovir dipivoxil), formerly referred to as GS 840, is an investigational, orally-administered, once-daily, reverse transcriptase inhibitor currently being studied in a variety of late-stage clinical trials to treat human immunodeficiency virus (HIV) and prevent cytomegalovirus (CMV) disease. PREVEON is administered as one tablet once daily, whereas most other anti-HIV compounds consist of multiple tablets or capsules taken several times a day."